Asia Pacific Cancer Targeted Therapy Market Report Outlook (2021–2031)

Innovations in Genomic Profiling and Biomarker Identification

The cancer targeted therapy market in Asia Pacific is driven by significant advancements in genomic profiling and biomarker discovery. Next-generation sequencing, liquid biopsy, and molecular diagnostics allow the detection of mutations such as EGFR, ALK, BRAF, RET, and PIK3CA with high precision. Countries such as Japan, South Korea, Singapore, and China have invested in central genomic testing infrastructure, enabling precision therapy adoption and patient stratification.

Public and private reimbursement programs are expanding, reducing cost barriers, and improving patient access. Regional clinical trials leverage molecular profiling for therapy matching, accelerating regulatory approvals. Artificial intelligence and bioinformatics enhance biomarker validation and treatment resistance monitoring. Growing genomic databases support real-world evidence, strengthening treatment guidelines and payer confidence. These factors collectively increase therapy adoption, enhance clinical outcomes, and sustain market growth in monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors.

Targeted Therapy Advances in Rare Mutation-Driven Cancers

The expansion of targeted therapies into rare cancers and genetically defined tumors represents a key opportunity in Asia Pacific. Advances in molecular profiling reveal actionable mutations in rare cancers, allowing tumor-agnostic treatment approaches targeting NTRK fusions, RET rearrangements, FGFR alterations, and BRAF mutations. Orphan drug pathways, conditional approvals, and market exclusivity enable faster commercialization and increased viability for rare indications.

Countries such as Japan, South Korea, Singapore, and Australia are adopting basket and umbrella trial designs to accelerate patient enrollment and clinical development. Access to molecular testing has improved rare mutation detection in emerging markets such as China, India, and Thailand, expanding the addressable population. Partnerships between multinational pharmaceutical companies and regional research institutions further support pipeline development and real-world evidence generation. As awareness of molecularly guided treatments grows, the market for niche targeted therapies is expected to expand rapidly, providing long-term opportunities and strengthening precision oncology adoption across Asia Pacific.

The "Asia Pacific Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Asia Pacific Cancer Targeted Therapy market size and forecast at regional and country levels for key segments covered under the scope
• Asia Pacific Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Asia Pacific Cancer Targeted Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Asia Pacific Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Asia Pacific Cancer Targeted Therapy market report is divided into: China, India, Japan, Australia, Bangladesh, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. China held the largest share in 2024.

The Asia Pacific cancer targeted therapy market exhibits significant regional variation. China is the most mature market, driven by high healthcare expenditure, strong precision oncology adoption, and robust insurance coverage for biomarker-guided therapies. South Korea follows closely with high clinical trial activity, advanced molecular testing infrastructure, and rapid uptake of immune checkpoint inhibitors. Singapore acts as a regional hub for clinical research and early therapy adoption, supported by government initiatives promoting personalized medicine. Australia combines high per-capita access to targeted therapies with strong public-private partnerships in oncology research. Emerging markets such as India, Thailand, and Malaysia are witnessing rapid growth due to increasing awareness of cancer care, improving hospital infrastructure, and expanding access to molecular diagnostics.

Reimbursement policies and cost-effectiveness analyses are gradually enhancing therapy affordability, while regional collaborations between multinational pharma, local biotech companies, and academic institutions improve access to cutting-edge treatments. Hospitals and specialized oncology centers dominate as end users, whereas private clinics and specialty pharmacies are increasingly investing in targeted therapies to expand service offerings. Collectively, the region presents a mix of mature and high-potential markets, where differentiated strategies—premium precision oncology in Japan, Singapore, and Australia, and affordability-driven expansion in China, India, and Southeast Asia—will define long-term market growth.

• The report includes qualitative and quantitative data in the Asia Pacific Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the Asia Pacific Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Asia Pacific Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Asia Pacific Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover Asia Pacific Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across China, India, Japan, Australia, Bangladesh, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The Asia Pacific Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Asia Pacific cancer targeted therapy market are:

• In October 2025, Raffles Medical Group signed an MOU with Gene Solutions to streamline patient identification and recruitment for global oncology clinical trials across Southeast Asia, enhancing access to precision cancer therapies through genomic screening collaboration.
• In March 2025, Bayer entered a global licensing agreement with China's Puhe BioPharma for an experimental PRMT5 inhibitor targeted therapy for MTAP‑deleted tumors, with clinical trial enrollment underway, signaling regional research momentum.